In chronic liver disease (CLD) patients with or without cirrhosis, existing studies on the outcomes with SARS-CoV-2 infection have limited generalizability. We used the National COVID Cohort Collaborative (N3C), a harmonized electronic health record (EHR) dataset of 6.4 million, to describe SARS-CoV-2 outcomes in patients with CLD and cirrhosis.